European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors

Cross-border multidisciplinary tumor boards enable networking and clinical collaboration between healthcare professionals in different countries. Surveillance strategies, off-label drug use, and increased participation in clinical trials are possible benefits to patients with rare gynecological tumors.